# GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC

> **NCT04251117** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Geneos Therapeutics** · enrollment: 36 (actual)

## Conditions studied

- HCC

## Interventions

- **BIOLOGICAL:** GNOS-PV02
- **BIOLOGICAL:** INO-9012
- **DRUG:** Pembrolizumab
- **DEVICE:** CELLECTRA®2000 EP Device

## Key facts

- **NCT ID:** NCT04251117
- **Lead sponsor:** Geneos Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-03-01
- **Primary completion:** 2024-11-29
- **Final completion:** 2028-11-29
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04251117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04251117, "GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04251117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*